Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954992 · ClinicalTrials.gov registry record · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
A Phase 3 study of Metastatic Pancreatic Adenocarcinoma, sponsored by Eleison Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 3
- Study locations
NCT01954992: Recruiting Phase 3 study of Metastatic Pancreatic Adenocarcinoma, sponsored by Eleison Pharmaceuticals.
NCT01954992 is a Phase 3 study of Metastatic Pancreatic Adenocarcinoma that is actively recruiting participants, run by Eleison Pharmaceuticals. The registered enrollment target is 480 participants, above the 77-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (523% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01954992, a Phase 3 study of Metastatic Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Eleison Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
Primary Outcome
Time from Randomization to death from any cause
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Glufosfamide
Study Locations (3)
California
- Innovative Clinical Research Institute - Whittier
Florida
- Moffitt Cancer Center - Tampa
Ohio
- Gabrail Cancer Center Research - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2014-04 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What NCT01954992 shows while recruiting
NCT01954992 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 77-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (523% higher).
The record links to 1 condition, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Fluorouracil is the first listed.
NCT01954992 reports a single indexed study location in California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01954992 about?
NCT01954992 is a clinical study titled "Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer". The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
What is the current status of trial NCT01954992?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2014-04. Estimated completion is 2026-12.
What conditions does trial NCT01954992 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT01954992?
The interventions under investigation include: Fluorouracil (DRUG), Glufosfamide (DRUG).
Who is sponsoring clinical trial NCT01954992?
This trial is sponsored by Eleison Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01954992 being conducted?
This trial has 3 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01954992's enrollment target sits among peer trials
480 2nd of 37 the highest of 37 other Metastatic Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
- NCT05279300 · 480 participants · Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia